These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10233876)

  • 21. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
    Vadhan-Raj S
    Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
    O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
    Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study.
    Ganser A; Lindemann A; Ottmann OG; Seipelt G; Hess U; Geissler G; Kanz L; Frisch J; Schulz G; Herrmann F
    Blood; 1992 May; 79(10):2583-91. PubMed ID: 1586711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function.
    Buescher ES; McIlheran SM; Banks SM; Vadhan-Raj S
    Exp Hematol; 1993 Oct; 21(11):1467-72. PubMed ID: 8405227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
    Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.
    Speyer JL; Mandeli J; Hochster H; Runowicz C; Wadler S; Wallach R; Cohen C; Oette D; Sorich J; Demakos E
    Gynecol Oncol; 1995 Mar; 56(3):387-94. PubMed ID: 7705673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
    Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of cytokines in children with recurrent solid tumors treated with intensive chemotherapy.
    Furman WL; Luo X; Marina N; Garrison L; Pratt CB; Meyer WH
    J Pediatr Hematol Oncol; 1998; 20(1):62-8. PubMed ID: 9482415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of transcriptional activation of the immediate early gene Egr-1 in response to PIXY321.
    Mignacca RC; Lee HJ; Kwon EM; Sakamoto KM
    Blood; 1996 Aug; 88(3):848-54. PubMed ID: 8704240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
    de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
    Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
    Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
    Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF).
    Smith SL; Bender JG; Berger C; Lee WJ; Loudovaris M; Martinson JA; Opotowsky JD; Qiao X; Schneidkraut M; Sweeney P; Unverzagt KL; Van Epps DE; Williams DE; Williams SF; Zimmerman TM
    J Hematother; 1997 Aug; 6(4):323-34. PubMed ID: 9377071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor.
    Bretti S; Gilleece MH; Kamthan A; Fitzsimmons L; Hicks F; Rowlands M; Bishop P; Picardo AM; Dexter TM; Scarffe JH
    Eur J Cancer; 1996 Jun; 32A(7):1171-8. PubMed ID: 8758249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation.
    Neidhart J; Mangalik A; Kohler W; Stidley C; Saiki J; Duncan P; Souza L; Downing M
    J Clin Oncol; 1989 Nov; 7(11):1685-92. PubMed ID: 2478670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.